Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.

Praxis Precision Medicines, a US-based gene therapy developer focusing central nervous system disorders, collected $110m in series C1 funding yesterday from investors including pharmaceutical firm Novo Holdings. Eventide Asset Management led the round, which also included Vida Ventures, Blackstone Life Sciences, OCV Partners, Avoro Capital Advisors, Surveyor Capital, Point72, Cormorant Asset Management, Qatar Investment Authority,…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.